- Posted in Resource Library

CureDuchenne Webinar with Wave Life Sciences

Wave will provide an overview of initial clinical trial results for WVE-N531 in individuals with Duchenne muscular dystrophy who are amenable to exon 53 skipping, as well as an overview of the potentially registrational FORWARD-53 study. 

Anne-Marie Li-Kwai-Cheung, MChem, MTOPRA, RAPS

Chief Development Officer

Wave Life Sciences

See more from same speaker

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

Related Resources

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate